Phaseline

Companies › NextPoint Therapeutics

NextPoint Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NPX372
B7-H7:CD3 bispecific antibody
PDCD7, CD3EPhase 1Metastatic Malignant NeoplasmApr 2027
NPX887
B7-H7/HHLA2 antagonistic monoclonal antibody
HHLA2Phase 1Metastatic Malignant NeoplasmAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07563829NPX372Phase 1Metastatic Malignant NeoplasmOncologyApr 2027
NCT06240728NPX887Phase 1Metastatic Malignant NeoplasmOncologyAug 2027

Targets

HHLA2 (1) PDCD7 (1) CD3E (1)

Companies with the same targets

Johnson & Johnson (Janssen) Regeneron Pharmaceuticals Amgen Roche AstraZeneca Tiziana Life Sciences Sanofi Shine-On Biomedical Pfizer Cullinan Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.